Pro-Atrial Natriuretic Peptide: A Novel Guanylyl Cyclase-A Receptor Activator That Goes Beyond Atrial and B-Type Natriuretic Peptides

Tomoko Ichiki, Brenda K. Huntley, S Jeson Sangaralingham, John C Jr. Burnett

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Objectives: The aim of this study was to determine if the atrial natriuretic peptide (ANP) precursor proANP is biologically active compared with ANP and B-type natriuretic peptide (BNP). Background: ProANP is produced in the atria and processed to ANP and activates the guanylyl cyclase receptor-A (GC-A) and its second messenger, cyclic guanosine monophosphate (cGMP). ProANP is found in the human circulation, but its bioavailability is undefined. Methods: The in vivo actions of proANP compared with ANP, BNP, and placebo were investigated in normal canines (667 pmol/kg, n = 5/group). cGMP activation in human embryonic kidney 293 cells expressing GC-A or guanylyl cyclase receptor-B was also determined. ProANP processing and degradation were observed in serum from normal subjects (n = 13) and patients with heart failure (n = 14) ex vivo. Results: ProANP had greater diuretic and natriuretic properties, with more sustained renal tubular actions, compared with ANP and BNP in vivo in normal canines, including marked renal vasodilation not observed with ANP or BNP. ProANP also resulted in greater and more prolonged cardiac unloading than ANP but much less hypotensive effects than BNP. ProANP stimulated cGMP generation by GC-A as much as ANP. ProANP was processed to ANP in serum from normal control subjects and patients with heart failure ex vivo. Conclusions: ProANP represents a novel activator of GC-A with enhanced diuretic, natriuretic, and renal vasodilating properties, and it may represent a key circulating natriuretic peptide in cardiorenal and blood pressure homeostasis. These results support the concepts that proANP may be a potential innovative therapeutic beyond ANP or BNP for cardiorenal diseases, including heart failure.

Original languageEnglish (US)
Pages (from-to)715-723
Number of pages9
JournalJACC: Heart Failure
Volume3
Issue number9
DOIs
StatePublished - Sep 1 2015

Fingerprint

Brain Natriuretic Peptide
Atrial Natriuretic Factor
Cyclic GMP
Kidney
Heart Failure
Diuretics
Canidae
peptide A
atrial natriuretic factor receptor A
Natriuretic Peptides
Second Messenger Systems
Serum
Vasodilation
Biological Availability
Homeostasis
Placebos
peptide B
Blood Pressure

Keywords

  • Atrial natriuretic peptides
  • CGMP
  • Kidney

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Pro-Atrial Natriuretic Peptide : A Novel Guanylyl Cyclase-A Receptor Activator That Goes Beyond Atrial and B-Type Natriuretic Peptides. / Ichiki, Tomoko; Huntley, Brenda K.; Sangaralingham, S Jeson; Burnett, John C Jr.

In: JACC: Heart Failure, Vol. 3, No. 9, 01.09.2015, p. 715-723.

Research output: Contribution to journalArticle

@article{3323d503547f4ae481c40b2ee43f24fd,
title = "Pro-Atrial Natriuretic Peptide: A Novel Guanylyl Cyclase-A Receptor Activator That Goes Beyond Atrial and B-Type Natriuretic Peptides",
abstract = "Objectives: The aim of this study was to determine if the atrial natriuretic peptide (ANP) precursor proANP is biologically active compared with ANP and B-type natriuretic peptide (BNP). Background: ProANP is produced in the atria and processed to ANP and activates the guanylyl cyclase receptor-A (GC-A) and its second messenger, cyclic guanosine monophosphate (cGMP). ProANP is found in the human circulation, but its bioavailability is undefined. Methods: The in vivo actions of proANP compared with ANP, BNP, and placebo were investigated in normal canines (667 pmol/kg, n = 5/group). cGMP activation in human embryonic kidney 293 cells expressing GC-A or guanylyl cyclase receptor-B was also determined. ProANP processing and degradation were observed in serum from normal subjects (n = 13) and patients with heart failure (n = 14) ex vivo. Results: ProANP had greater diuretic and natriuretic properties, with more sustained renal tubular actions, compared with ANP and BNP in vivo in normal canines, including marked renal vasodilation not observed with ANP or BNP. ProANP also resulted in greater and more prolonged cardiac unloading than ANP but much less hypotensive effects than BNP. ProANP stimulated cGMP generation by GC-A as much as ANP. ProANP was processed to ANP in serum from normal control subjects and patients with heart failure ex vivo. Conclusions: ProANP represents a novel activator of GC-A with enhanced diuretic, natriuretic, and renal vasodilating properties, and it may represent a key circulating natriuretic peptide in cardiorenal and blood pressure homeostasis. These results support the concepts that proANP may be a potential innovative therapeutic beyond ANP or BNP for cardiorenal diseases, including heart failure.",
keywords = "Atrial natriuretic peptides, CGMP, Kidney",
author = "Tomoko Ichiki and Huntley, {Brenda K.} and Sangaralingham, {S Jeson} and Burnett, {John C Jr.}",
year = "2015",
month = "9",
day = "1",
doi = "10.1016/j.jchf.2015.03.015",
language = "English (US)",
volume = "3",
pages = "715--723",
journal = "JACC: Heart Failure",
issn = "2213-1779",
publisher = "Elsevier BV",
number = "9",

}

TY - JOUR

T1 - Pro-Atrial Natriuretic Peptide

T2 - A Novel Guanylyl Cyclase-A Receptor Activator That Goes Beyond Atrial and B-Type Natriuretic Peptides

AU - Ichiki, Tomoko

AU - Huntley, Brenda K.

AU - Sangaralingham, S Jeson

AU - Burnett, John C Jr.

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Objectives: The aim of this study was to determine if the atrial natriuretic peptide (ANP) precursor proANP is biologically active compared with ANP and B-type natriuretic peptide (BNP). Background: ProANP is produced in the atria and processed to ANP and activates the guanylyl cyclase receptor-A (GC-A) and its second messenger, cyclic guanosine monophosphate (cGMP). ProANP is found in the human circulation, but its bioavailability is undefined. Methods: The in vivo actions of proANP compared with ANP, BNP, and placebo were investigated in normal canines (667 pmol/kg, n = 5/group). cGMP activation in human embryonic kidney 293 cells expressing GC-A or guanylyl cyclase receptor-B was also determined. ProANP processing and degradation were observed in serum from normal subjects (n = 13) and patients with heart failure (n = 14) ex vivo. Results: ProANP had greater diuretic and natriuretic properties, with more sustained renal tubular actions, compared with ANP and BNP in vivo in normal canines, including marked renal vasodilation not observed with ANP or BNP. ProANP also resulted in greater and more prolonged cardiac unloading than ANP but much less hypotensive effects than BNP. ProANP stimulated cGMP generation by GC-A as much as ANP. ProANP was processed to ANP in serum from normal control subjects and patients with heart failure ex vivo. Conclusions: ProANP represents a novel activator of GC-A with enhanced diuretic, natriuretic, and renal vasodilating properties, and it may represent a key circulating natriuretic peptide in cardiorenal and blood pressure homeostasis. These results support the concepts that proANP may be a potential innovative therapeutic beyond ANP or BNP for cardiorenal diseases, including heart failure.

AB - Objectives: The aim of this study was to determine if the atrial natriuretic peptide (ANP) precursor proANP is biologically active compared with ANP and B-type natriuretic peptide (BNP). Background: ProANP is produced in the atria and processed to ANP and activates the guanylyl cyclase receptor-A (GC-A) and its second messenger, cyclic guanosine monophosphate (cGMP). ProANP is found in the human circulation, but its bioavailability is undefined. Methods: The in vivo actions of proANP compared with ANP, BNP, and placebo were investigated in normal canines (667 pmol/kg, n = 5/group). cGMP activation in human embryonic kidney 293 cells expressing GC-A or guanylyl cyclase receptor-B was also determined. ProANP processing and degradation were observed in serum from normal subjects (n = 13) and patients with heart failure (n = 14) ex vivo. Results: ProANP had greater diuretic and natriuretic properties, with more sustained renal tubular actions, compared with ANP and BNP in vivo in normal canines, including marked renal vasodilation not observed with ANP or BNP. ProANP also resulted in greater and more prolonged cardiac unloading than ANP but much less hypotensive effects than BNP. ProANP stimulated cGMP generation by GC-A as much as ANP. ProANP was processed to ANP in serum from normal control subjects and patients with heart failure ex vivo. Conclusions: ProANP represents a novel activator of GC-A with enhanced diuretic, natriuretic, and renal vasodilating properties, and it may represent a key circulating natriuretic peptide in cardiorenal and blood pressure homeostasis. These results support the concepts that proANP may be a potential innovative therapeutic beyond ANP or BNP for cardiorenal diseases, including heart failure.

KW - Atrial natriuretic peptides

KW - CGMP

KW - Kidney

UR - http://www.scopus.com/inward/record.url?scp=84941050521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941050521&partnerID=8YFLogxK

U2 - 10.1016/j.jchf.2015.03.015

DO - 10.1016/j.jchf.2015.03.015

M3 - Article

C2 - 26362447

AN - SCOPUS:84941050521

VL - 3

SP - 715

EP - 723

JO - JACC: Heart Failure

JF - JACC: Heart Failure

SN - 2213-1779

IS - 9

ER -